NCT05747729View on ClinicalTrials.gov

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2026

Conditions
Neuroendocrine Carcinoma
Interventions
DRUG

Surufatinib and Serplulimab

"Surufatinib: Safety lead-in : Oral, QD, starting dose 250 mg, adjusted according to DLT. Dose expansion: administration according to the dose determined in the safety lead-in phase.~Serplulimab: 300 mg intravenous infusion on day 1, repeated every 3 weeks."

Trial Locations (1)

430022

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT05747729 - A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. | Biotech Hunter | Biotech Hunter